重癥肌無力|每年29億美元年銷售額？一文解析治療重癥肌無力新藥efgartigimod( 四 ) 抗體|igg|銷售額

樂城先行區是海南自貿港建設的重點園區，也是中國的“醫療特區” ，可以同步引進國際創新藥械。對于罕見病的治療藥物，也是樂城先行區藥品引進的重點。 7月5日，國內已經有首位重癥肌無力患者在博鰲樂城接受了efgartigimod首次治療。
如果《過把癮》可以拍個續集，也許可以讓重癥肌無力患者方言去海南治個病？
參考文獻：
[1
Chen JTian D-C Zhang C et al. Incidence mortality and economic burden ofmyasthenia gravis in China: A nationwide population-based study. The LancetRegional Health – Western Pacific 2020;5:
[2
Heo Y-A. Efgartigimod: First Approval.Drugs 2022; 82: 341-348.
[3
Vincent A ， DavisJ N.Anti-acetylcholine receptor antibodies. Journal of Neurology Neurosurgery& Psychiatry 1980; 43:590.
[4
Al-Zwaini I JAli A L M. IntroductoryChapter: Myasthenia Gravis-An Overview. Selected Topics in Myasthenia Gravis 2019;
[5
Vaccaro C Zhou J Ober R J et al.Engineering the Fc region of immunoglobulin G to modulate in vivo antibodylevels. Nature Biotechnology 2005;23: 1283-1288.
[6
Ulrichts P Guglietta A Dreier T etal. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reducesIgGs in humans. The Journal of clinical investigation 2018; 128: 4372-4386.
[7
Howard J F Bril V Burns T M et al.Randomized phase 2 study of FcRn antagonist efgartigimod in generalizedmyasthenia gravis. Neurology 2019;92: e2661.
[8
Howard J F Bril V Vu T et al. Safetyefficacy and tolerability of efgartigimod in patients with generalisedmyasthenia gravis (ADAPT): a multicentre randomised placebo-controlled phase3 trial. The Lancet Neurology 2021;20: 526-536.
[9
Newland A C Sánchez‐González B Rejt?L et al. Phase 2 study of efgartigimod a novel FcRn antagonist in adultpatients with primary immune thrombocytopenia. American journal of hematology 2020; 95: 178-187.
[10
Goebeler M Bata‐Cs?rg? Z De Simone C etal. Treatment of pemphigus vulgaris and foliaceus with efgartigimod a neonatalFc receptor inhibitor: a phase II multicentre open‐label feasibility trial.British Journal of Dermatology 2022;186: 429-439.